Peter F. Orio, III, DO, MS

Director of Genitourinary Brachytherapy at the Department of Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center, Boston, USA

Dr. Orio is the Vice Chair and Medical Director of Network Operations and Director of Genitourinary Brachytherapy at the Department of Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center, a Senior Physician at Dana-Farber Cancer Institute and an Assistant Professor of Radiation Oncology at Harvard Medical School. 

Dr. Orio completed his residency in Radiation Oncology at the University of Washington and Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance) in 2006 and after graduation held numerous leadership positions prior to returning to Boston, Massachusetts in 2010 to join the Dana-Farber/Brigham and Women’s Cancer Center.

Dr. Orio holds several leadership positions in the American Society of Radiation Oncology (ASTRO), serving as Vice Chair of the Code Development and Code Valuation Committee and Advisor to the American Medical Society (AMA) RVS Update (RUC) Committee and Centers for Medicare and Medicaid Services (CMS). He remains active in the American Brachytherapy Society, where he chairs the Socioeconomic Committee and is a Director at Large on the Board of Directors. Dr. Orio received the American Brachytherapy Society’s Presidential Award in 2014 for his leadership and numerous efforts on behalf of the organization and was Scientific Chair of the 2016 ABS/GEC-ESTRO World Congress of Brachytherapy.

In addition to his administrative positions, Dr. Orio has made academic contributions to the field of genitourinary malignancies where he has authored or coauthored over 50 publications in the field of prostate cancer and prostate brachytherapy. Dr. Orio focuses his clinical efforts on advancing innovative solutions for the safe delivery of radioactive isotopes as a cost-effective and efficacious treatment. He continues to work towards advancing radiation therapy and brachytherapy planning and delivery for prostate cancer patients internationally.